Try our Advanced Search for more refined results

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Track this case

Case Number:

2:17-md-02785

Court:

Kansas

Nature of Suit:

Personal Inj. Prod. Liability

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Daniel D. Crabtree

Firms

Companies

Sectors & Industries:

  1. April 27, 2020

    Judge Keeps EpiPen Expiration Date Suit Out Of MDL

    A Kansas federal judge on Monday refused to roll claims that Mylan and Pfizer manipulated EpiPen expiration dates into multidistrict litigation over an alleged scheme to inflate prices for the life-saving allergy medication.

  2. March 31, 2020

    EpiPen Buyers Can't Inject RICO Suit Into MDL, Court Told

    Claims that Mylan and Pfizer manipulated EpiPen expiration dates to force patients to refill prescriptions more often than necessary do not belong in multidistrict litigation over an alleged scheme to inflate prices for the life-saving allergy medication, the companies told a Kansas federal judge.

  3. March 24, 2020

    EpiPen Buyers Tear Into Mylan, Pfizer Bid For Cert. Review

    EpiPen buyers suing Mylan and Pfizer over the exorbitant cost of the emergency allergy treatment are fighting the drugmakers' push for a Tenth Circuit review of their class certification win, arguing a mid-case appeal is only warranted in "death knell cases" and this isn't one of them.

  4. March 19, 2020

    Mylan, Pfizer Want EpiPen Row Paused For Class Cert. Appeal

    Mylan and Pfizer asked a Kansas federal court to pause a class action accusing the drugmakers of scheming to inflate prices of the emergency allergy treatment EpiPen while they try to appeal last month's class certification ruling to the Tenth Circuit.

  5. February 27, 2020

    Court Certifies RICO, State Antitrust Classes In EpiPen MDL

    A Kansas federal court on Thursday certified classes of EpiPen buyers seeking damages for racketeering and state antitrust violations in a suit accusing Mylan and Pfizer of scheming to inflate the price of the emergency allergy treatment.

  6. January 24, 2020

    Sanofi, Mylan Spar Over Surescripts Ruling In EpiPen Fight

    Mylan told a Kansas federal judge on Friday that Sanofi is wrong to argue that a recent ruling in the Federal Trade Commission's monopolization case against Surescripts supports allegations that Mylan violated antitrust law in an effort to maintain the dominance of its EpiPen.

  7. August 20, 2019

    Pfizer Says It Shouldn't Be Included In EpiPen Class Cert. Bid

    Pfizer is fighting to keep a Kansas federal judge from certifying five classes of consumers who say the pharmaceutical giant had a hand in delaying the entry of a generic version of the EpiPen as the price of the branded emergency allergy treatment continued to skyrocket.

  8. August 06, 2019

    Mylan Blasts '11th Hour' Discovery Push In EpiPen Row

    Consumers shouldn't be allowed more time for discovery in multidistrict litigation over EpiPen price hikes, Mylan has told a Kansas federal judge, blasting what it described as a last-minute request predicated on failings for which the plaintiffs "are entirely at fault."

  9. August 02, 2019

    Mylan CEO Must Face New EpiPen Deposition, Judge Rules

    Consumers can depose Mylan Inc.'s CEO again in multidistrict litigation over EpiPen price hikes because new and "highly relevant" information has surfaced about potential maneuvers to block lower-cost competition, a Kansas federal judge ruled Friday.

  10. July 23, 2019

    EpiPen Buyers Target Mylan CEO After Teva Disclosures

    Consumers are demanding another deposition of Mylan's CEO as part of multidistrict litigation over skyrocketing EpiPen prices, citing allegedly incriminating documents produced by Teva Pharmaceuticals in recent weeks.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!